



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/725 // (A61K 31/725, 31:715, 31:00)	A1	(11) International Publication Number: WO 97/20564 (43) International Publication Date: 12 June 1997 (12.06.97)
(21) International Application Number: PCT/CA96/00793 (22) International Filing Date: 29 November 1996 (29.11.96) (30) Priority Data: 2,164,260 1 December 1995 (01.12.95) CA 2,173,037 29 March 1996 (29.03.96) CA (71) Applicant (for all designated States except US): HYAL PHARMACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): GUSTAFSON, Stefan [SE/SE]; Stackmastarvagen 15, S-756 47 Uppsala (SE). (74) Agent: HUGHES, Etigson; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TARGETING OF DOSAGES OF MEDICINE AND THERAPEUTIC AGENTS AND OTHER GLYCOSAMINOGLYCANS (GAGS)		
(57) Abstract A method of treating a disease or condition in a human treatable by a medicine and/or therapeutic agent which may be transported by an agent to the site in need of treatment in the body and which agent may also transport the medicine and/or therapeutic agent to the liver (by for example, the transport agent binding to receptors on the liver) is provided comprising: (a) administering an effective non-toxic amount of a first agent which does not bind to receptors at the site in need of treatment but which binds with receptors of the liver thereby "down regulating" the liver; and, (b) thereafter administering an effective non-toxic amount of a medicine and/or therapeutic agent and an effective amount of a second agent which is a transport agent and is a different agent from the first agent which binds to the site in need of treatment and would be capable of binding to the sites of the liver if the liver had not been "down regulated" so that its binding capacity for the second agent has been substantially reduced by the up-take by the liver of the first agent administered under sub-paragraph (a) by for example, binding with the scavenger receptors of the liver.		